Investing

George Soros Top Equity Holdings (AAPL, AUXL, BFLY, CBI, CMG, CRUS, COV, MAPP, POT, SVNT)

This week we got to see critical SEC filings showing holdings of many key and influential investors.  Included in these filings were billionaire George Soros, a billionaire whom is loved by some and much less ‘well thought of’ by others over his currency trading history of over his MoveOn.org attempts.  Either way, investors still watch Soros.  These are the holdings of Soros Fund Management LLC as of December 31, 2007.  These were listed as the top holdings and are not at all his entire positions.  Soros Fund Management LLC was listed as having some $2.269 Billion in the total filing, and these positions here only equate to $360+ million, so there are many more positions.  As with all of these holdings, these positions may have changed or been eliminated as of the dates noted.  Here is a summary of his larger positions with a dollar amount provided by Soros as filer and a share count:

  • Apple Inc. (NASDAQ: AAPL)   $32,000,000;  161,550 shares
  • Auxilium Pharma (NASDAQ: AUXL)   $36,473,000;  1,216,180 shares
  • Bluefly Inc. (NASDAQ: BFLY)   $36,451,000;  48,601,156 shares… an old favorite of his…
  • Chicago Bridge & Iron Co. (NYSE: CBI)   $29,743,000;  492,100 shares
  • Chipotle Mexican Grill, Inc. (NYSE: CMG)  $32,404,000;  220,332 shares
  • Cirrus Logic Inc. (NASDAQ: CRUS)   $24,376,000;  4,616,666 shares
  • Covidien, Ltd. (NYSE: COV)   $32,194,000;  726,900 shares
  • MAP Pharmaceuticals (NASDAQ: MAPP)   $71,374,000;  4,076,169
  • Potash Corp. (NYSE: POT)   $37,933,000;  263,500 shares
  • Savient Pharmaceuticals (NASDAQ: SVNT)   $25,002,000;  1,088,461 shares

As Soros himself says …."Contrary to the tenets of market fundamentalism, financial markets do not tend towards equilibrium; they are crisis prone."   

Other billionaires and their holdings filed this week:
Bill Gates
Carl Icahn
Warren Buffett

Jon C. Ogg
February 16, 2008

 

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.